FloBiotech develops the FloCells™ platform, a proprietary human‑relevant tauopathy modeling system that enables earlier risk assessment and more predictive drug development for neurodegenerative diseases such as Alzheimer’s. By integrating precision therapeutics like their Clusterin program, the platform aims to enhance the brain’s natural defenses and improve translational success, supported by collaborations with leading neuroscience institutes across Europe.
Funding
$550K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Neurodegenerative drug development suffers from low translational success because existing models do not accurately recapitulate human tau pathology, leading to costly clinical failures and limited therapeutic options for diseases such as Alzheimer’s.
Solution
FloBiotech addresses this gap with its proprietary FloCells™ platform, which generates human‑relevant tauopathy models for early risk assessment in drug pipelines. The platform enables researchers to evaluate candidate compounds against physiologically accurate tau-driven disease mechanisms, improving the likelihood of clinical efficacy. In parallel, FloBiotech is developing a precision therapy that enhances soluble Clusterin, a protein that supports the brain’s innate defenses against toxic aggregates. By combining advanced disease modeling with a targeted therapeutic approach, the company aims to reduce the clinical and economic burden of Alzheimer’s and related disorders.
Target Audience
Primary customers are pharmaceutical and biotech companies developing neurodegenerative therapies, as well as academic research groups focused on tau biology and drug discovery.
Features
- Human‑derived cellular models that faithfully reproduce tau aggregation and downstream neurodegenerative processes
- Scalable FloCells™ workflow compatible with high‑throughput screening and mechanistic studies
- Integrated biomarker readouts to quantify tau pathology, cell viability, and neuroinflammatory responses
- Precision‑medicine Clusterin program that increases soluble Clusterin levels to bolster endogenous neuroprotection
- Collaborative framework with leading neuroscience institutes across Europe to validate and expand the platform